Effect of Evolocumab on Chronic Total Occlusions (EVOLO-CTO)
NCT05623995
·
clinicaltrials.gov ↗
PHASE4
Phase
UNKNOWN
Status
200
Enrollment
OTHER
Sponsor class
Conditions
In-stent Restenosis
Major Adverse Cardiovascular Events
Interventions
DRUG:
PCSK9 inhibitor
DRUG:
Statin
Sponsor
Lin Zhao